Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Next Previous
Trial Profile

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NP G2 044 (Primary) ; Programmed cell death 1 receptor antagonists (Primary)
  • Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novita Pharmaceuticals

Most Recent Events

  • 11 Jun 2025 Planned End Date changed from 1 Sep 2025 to 1 Mar 2026.
  • 11 Jun 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Dec 2025.
  • 22 May 2025 According to Novita Pharmaceuticals media release, an amendment to the study is currently underway to open additional cohorts, which will aim to further evaluate the combination of NP-G2-044 with anti-PD-1 therapy across patient populations and solid tumor subtypes. Future analysis will also explore biomarkers for response prediction and mechanisms of resistance, guiding personalized approaches in treatment-resistant cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top